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Neuroferritinopathy is a rare progressive disease showing 
extrapyramidal symptoms such as chorea, dystonia, or parkin-
sonism and cognitive impairment as well as an accumulation 
of iron in the basal ganglia. Low serum ferritin levels and cavi-
tation of the basal ganglia in brain magnetic resonance (MR) 
imaging are frequently observed in patients with neuroferri-
tinopathy.1 Mutations in the FTL1 gene encoding the ferritin 
light chain are the cause of neuroferritinopathy, and four inser-
tional mutations were identified in four separate Asian fami-
lies.2-5 Here, we report a Korean patient with neuroferritinopathy 
who showed cystic lesions in the basal ganglia and a novel muta-
tion in FTL1.
A 43-year-old woman presented with involuntary move-
ment in her arms and mouth. Her symptoms had gradually 
worsened until she first visited our clinic at age 47. She had no 
perinatal and developmental problems, and no history of pre-
vious neurological and psychiatric illnesses. Her parents and 
five siblings did not have neurological illness. In a neurological 
examination, she showed very mild choreic dyskinesia in her 
shoulders, hands and feet at rest. When she was trying to speak 
or move her limbs, her limb dyskinesia temporarily worsened 
and dystonic spasms appeared in her lips and neck. Sometimes, 
she made a sniffing sound. She showed mild dystonia and mild 
bradykinesia in her fingers, but she did not show rigidity, atax-
ia, and gait abnormality. Laboratory studies showed no abnor-
mality in her complete blood count, routine chemistry, thyroid 
function tests, and autoimmune screening tests. Her serum ce-
ruloplasmin, iron, transferrin, and ferritin (20.9 μg/L; reference 
10–122 μg/L) levels were normal. Her brain MR angiography 
was unremarkable. Meanwhile, her brain MR imaging showed 
bilateral globus pallidus lesions consisting of three layers with a 
cystic core, middle, and outer layer. The cystic core exhibited hy-
pointensity in T1-weighted and fluid-attenuated inversion re-
covery (FLAIR) images. The middle layer surrounding the core 
was hypointense in T1 and hyperintense in FLAIR images, 
while the outer layer was hyperintense in T1 and hypointense in 
FLAIR and susceptibility-weighted images. This hypointensity 
lesion extended downward to the substantia nigra (Figure 1A). 
No other cortical or subcortical region showed abnormality. 
Dopamine transporter positron emission tomography imaging 
showed a diffuse mild reduction of striatal uptake. Whole ge-
nome sequencing and subsequent Sanger sequencing confirmed 
a novel mutation in exon 4 of FTL1 (c.439_440het_dupG, 
NM_000146.3), which causes a frameshift (p.D147GfsX34, 
NP_000137.2) leading to truncation of the ferritin light chain 
protein (Figure 1B). Her choreic movement partially respond-
ed to an oral haloperidol treatment.
Until recently, ten mutations in FTL1 were found in more 
than 90 patients with neuroferritinopathy.5,6 Except for one mis-
sense mutation found in a Portuguese individual with gypsy 
ancestry, all mutations, including the mutation found in our pa-
tient, were insertional mutations in exon 4 that caused a frame-
shift; therefore, exon 4 is considered to be a mutational hot spot 
in the FTL1 gene regardless of ethnicity.6 Patients with FTL1 
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mutations that cause conformational changes only in helix-E 
of the ferritin light chain protein were likely to present a more 
severe phenotype than those with mutations leading to disrup-
tion of both helix-D and E.3 Focal onset of chorea or dystonia 
in the late 30s and frequent associations with bulbar symptoms 
such as orolingual dyskinesia are the most typical clinical pre-
sentations of the 460InsA mutation, and it is the most frequent 
type of FTL1 mutation that causes changes in both helix D and 
E.1 The FTL1 mutation found in our patient also causes pro-
duction of both abnormal helix-D and E, and her clinical mani-
festations closely resemble the typical presentation of an FTL1 
mutation producing abnormal helix-D and E.
Although the accumulation of iron can be found in the cere-
bral and cerebellar cortical surfaces appearing as thin hypoin-
tense lines in susceptibility-weighted imaging, referred to as a 
pencil-lining sign,7 iron accumulation in the subcortical nuclei 
combined with cystic degeneration in the pallidum and even in 
the putamen are the most characteristic features in MR imag-
ing, especially in advanced cases.1,6 Lesions with hyperintensity 
in T1-weighted and hypointensity in iron-sensitive MR images 
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Figure 1. Brain MR images and the DNA sequence of the neuroferritinopathy patient. A: Fluid-attenuated inversion recovery (FLAIR) MR 
images show a trilamellar cystic lesion in the pallidum. T1-weighted and susceptibility-weighted (SWI) MR images show a cystic core and a 
surrounding rim of iron deposition. B: Sanger sequencing results of the proband showing a novel frameshift mutation (c.439_440het_dupG, 
NM_000146.3) in the FTL1 gene.
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appear in the basal ganglia, thalamus, substantia nigra, red nucle-
us, and dentate nucleus in asymptomatic carriers; the pallidal le-
sion found in advanced patients exhibits a typical cystic core with 
hypointensity in T1-weighted and FLAIR MR images as well as 
a surrounding rim with hyperintensity in T1-weighted and hy-
pointensity in iron-sensitive MR images.1 Interestingly, FLAIR 
MR images of the current patient exhibited trilamellar intensi-
ty around the cystic lesion, which may represent different stag-
es of expanding pathology, consisting of an outer layer with 
iron deposition, a middle layer with suspicious on-going de-
generative process and gliosis, and a cystic core with tissue loss. 
The FTL1 mutation may cause impaired sequestration of iron 
by ferritin, thereby leading to the accumulation of free iron, pro-
duction of free radicals, increased oxidative stress, and neurode-
generation.6 This hypothetical cascade of pathogenesis may ex-
plain the different stages of lesions shown in the MR imaging.
In summary, we found a novel c.439_440het_dupG mutation 
in exon 4 of FTL1 in a patient presenting with typical clinical 
manifestations of neuroferritinopathy, and trilamellar cystic de-
generation in the FLAIR MR image may be another radiological 
sign that characterizes neuroferritinopathy.
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